Inncardio, Inc. Announces Agreement With Sigmoid Biotechnologies Ltd.

Inncardio, Inc. Announces Agreement With Sigmoid Biotechnologies
Ltd. 


NEW YORK, April 18  /PRNewswire-FirstCall/ -- Inncardio, Inc. (OTC:INDO)
(BULLETIN BOARD: INDO) , a company founded by Bioaccelerate Holdings Inc.
(OTC:BACL) (BULLETIN BOARD: BACL) , today announced an agreement with Sigmoid
Biotechnologies Ltd., based in Dublin, Ireland, for the co-development and
license of two novel formulations of established drugs. Upon approval and
commercialization, these drugs, which utilize Sigmoid's proprietary delivery
and formulation technology, are anticipated to achieve combined peak annual
sales of more than $1.0bn.  Terms of the agreement were not disclosed.

"We believe the combination of the products we are developing and the
technological expertise provided by Sigmoid Biotechnologies will extend and
enhance our current product development portfolio," stated Bernard Ross, Chief
Executive Officer of Inncardio. "This agreement represents a further execution
of Bioaccelerate's strategy to invest in new formulations of well-established
drugs and the rapid development and value enhancement of new drugs.  Our
business model provides investors with a balance of lower risk, near-to-market
development products and pre-clinical blockbuster opportunities."

"This agreement provides an accelerated route to market for two of our lead
products. We anticipate that the first of our co-developments with Inncardio,
our first with Bioaccelerate, will be ready for marketing approval in under 24
months," said Ivan Coulter, Ph.D., Chief Executive Officer of Sigmoid
Biotechnologies.

About Sigmoid Biotechnologies Ltd.

Founded by former Elan and NTera executives in 2003, Sigmoid Biotechnologies is
focused on the development of a proprietary drug delivery technology,
LEDDS(TM).  Uniquely, LEDDS is positioned to enable the development of
controlled release of drugs that are formulated in liquid or emulsion format, a
process that previously was suited only to drugs that are available in powder
form.  Thus, LEDDS represents a unique opportunity in drug delivery.

As a broadly applicable, patent-protected technology LEDDS is positioned to
exploit opportunities to improve therapeutics in the pharmaceutical,
biopharmaceutical veterinary and nutraceutical industries.  Sigmoid has
identified several such opportunities that will benefit from a range of LEDDS
controlled release formats as well as from the development of novel drug
combination approaches that will lead to improved efficacy or bioavailability.

About Inncardio, Inc.

Inncardio, Inc., a company founded by Bioaccelerate Holdings Inc. (OTC:BACL)
(BULLETIN BOARD: BACL) , is a biotechnology company engaged in the acquisition,
development and commercialization of treatments and therapies targeted at
various cardiovascular and metabolic diseases. The Company's management team is
focused on both the ongoing development of Inncardio's products to build value
prior to partnering and the in-licensing of additional cardiovascular products
to further enhance the Company's commercial value. The Company currently has
six compounds in its portfolio. The three lead programs are novel formulations
of approved drugs where, re-formulation is predicted to either improve efficacy
or minimize side effects.  The three other products are novel compounds and are
in pre-clinical development. Inncardio's lead development product is being
investigated for use as a post-stroke therapy that has a novel delivery profile
and is targeted to reduce the incidence and severity of ischemic deficits in
patients with subarachnoid hemorrhage from rupture intracranial berry aneurysm.

Bioaccelerate Safe Harbor Statement

Certain statements contained herein are "forward-looking" statements (as such
term is defined in the Private Securities Litigation Reform Act of 1995).
Because these statements include risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking
statements. Specifically, factors that could cause actual results to differ
materially from those expressed or implied by such forward-looking statements
include, but are not limited to: risks associated with pre-clinical and
clinical developments in the biopharmaceutical industry in general and in
Inncardio or Bioaccelerate's compounds under development in particular; the
potential failure of Inncardio or Bioaccelerate's compounds under development
to prove safe and effective for treatment of disease; uncertainties inherent in
the early stage of Inncardio or Bioaccelerate's compounds under development;
failure to successfully implement or complete clinical trials; failure to
receive marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or strategic
initiatives that change Inncardio or Bioaccelerate's business, structure or
projections; the development of competing products; uncertainties related to
Inncardio or Bioaccelerate's dependence on third parties and partners; and
those risks described in the filings with the SEC, all of which are under
Bioaccelerate's prior name Mobile Design Concepts, Inc. and Inncardio's prior
name Softwall Equipment Corp. Inncardio and Bioaccelerate disclaim any
obligation to update these forward-looking statements.

   CONTACT:

   Bioaccelerate Holdings Inc.
   Christopher O'Toole
   Senior Vice President
   212-332 4387

   Inncardio Inc.
   Bernard Ross
   Chief Executive Officer
   [phone]

   Sigmoid Biotechnologies Ltd.
   Ivan Coulter
   Chief Executive Officer
   [phone]

   Matthew Haines (Investors)
   Vice President
   Noonan Russo
   212-845-4235

   Emily Poe (Media)
   Vice President
   Noonan Russo
   212-845-4266


Ltd.

DATASOURCE: Inncardio Inc.; Bioaccelerate Holdings Inc.; Sigmoid
Biotechnologies



CONTACT:  Christopher O'Toole, Senior Vice President of Bioaccelerate

Holdings Inc., [phone]; or Bernard Ross, Chief Executive Officer of

Inncardio Inc., [phone]; or Ivan Coulter, Chief Executive Officer of

Sigmoid Biotechnologies Ltd., [phone]; or Investors: Matthew Haines,

Vice President, [phone], or Emily Poe, Vice President, [phone],

both of Noonan Russo, for Bioaccelerate Holdings Inc. and Inncardio Inc.

Copyright